Yeleswaram Krishnaswamy, Chief Development Officer at Rapport Therapeutics ($RAPP), made one open market sale of common shares in the last year, totaling $85,342. His most recent sale occurred on December 31, 2025. This activity ranks 9,791st among 11,678 insiders in our database, well below the average sale amount of 8.6 million dollars over about six transactions. He recorded no open market purchases.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 25, 2026 | Rapport Therapeutics, Inc. | $RAPP | Yeleswaram Krishnaswamy | Chief Development Officer | S | Common Stock | 10115 | $29.99 | 286,876.0000 | 47,661,138 | 3.41% | 0.02% |
| Feb. 2, 2026 | Rapport Therapeutics, Inc. | $RAPP | Yeleswaram Krishnaswamy | Chief Development Officer | A | Stock Option (Right to Buy) | 120000 | $0.00 | 120,000.0000 | 47,661,138 | 9999.99% | 0.25% |
| Dec. 31, 2025 | Rapport Therapeutics, Inc. | $RAPP | Yeleswaram Krishnaswamy | Chief Development Officer | A | Common Stock | 9000 | $0.00 | 299,831.0000 | 47,661,138 | 3.09% | 0.02% |
| Dec. 31, 2025 | Rapport Therapeutics, Inc. | $RAPP | Yeleswaram Krishnaswamy | Chief Development Officer | S | Common Stock | 2840 | $30.05 | 296,991.0000 | 47,661,138 | 0.95% | 0.01% |
| Feb. 3, 2025 | Rapport Therapeutics, Inc. | $RAPP | Yeleswaram Krishnaswamy | Chief Development Officer | A | Stock Option (Right to Buy) | 110000 | $0.00 | 110,000.0000 | 0 | 9999.99% | 0.00% |
| June 6, 2024 | Rapport Therapeutics, Inc. | $RAPP | Yeleswaram Krishnaswamy | Chief Development Officer | A | Stock Option (Right to Buy) | 84904 | $0.00 | 84,904.0000 | 0 | 9999.99% | 0.00% |